|Bid||148.00 x 900|
|Ask||250.00 x 1100|
|Day's Range||175.13 - 182.02|
|52 Week Range||85.22 - 196.12|
|Beta (5Y Monthly)||1.36|
|PE Ratio (TTM)||42.04|
|Earnings Date||Jul 26, 2021 - Jul 30, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||180.25|
Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced that it will report its second quarter 2021 financial results after the market close on Monday, July 26, 2021. The Company will host a conference call the following morning, Tuesday, July 27, 2021, at 9:00 a.m. ET to discuss these results.
Polen Capital, an investment management firm, published its “Polen U.S. SMID Company Growth Composite” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 2.35% was delivered by the fund for the first quarter of 2021, trailing its Russell 2500 Growth benchmark that delivered a 2.49% gain for […]
In the healthcare space, Dexcom (NASDAQ: DXCM), CVS Health (NYSE: CVS), and Medpace Holdings (NASDAQ: MEDP) all have momentum and strong fundamentals on their side. Dexcom, which makes wearable continuous glucose monitoring devices and the software for them, has the rise of the number of diabetes patients worldwide fueling its growth. CVS, known as a drug store company but firmly established as a medical insurer thanks to its purchase of Aetna, is helped by increased foot traffic in its stores as vaccination rates increase in the U.S. Medpace has benefited as companies turn to clinical research organizations to more seamlessly run their drug trials and approval processes for new medical therapies and devices.